| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3374398 | Journal of Infection | 2015 | 6 Pages |
Abstract
SummaryCapsular group B Neisseria meningitidis is one of the leading causes of death in developed countries. A new vaccine (4CMenB) has recently been developed which was found to have an acceptable safety profile in clinical studies and to be immunogenic. This review examines the evidence supporting the licensure of the 4CMenB vaccine and discusses recommendations for its use.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Simon B. Drysdale, Andrew J. Pollard,